Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.

Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, Taylor AA, Giordano TP, Sekhar RV, Clark P, Cuevas-Sanchez E, Kamble S, Ballantyne CM, Pownall HJ.

J Clin Endocrinol Metab. 2011 Jul;96(7):2236-47. doi: 10.1210/jc.2010-3067.

2.
3.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
4.

The therapeutic role of niacin in dyslipidemia management.

Boden WE, Sidhu MS, Toth PP.

J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):141-58. doi: 10.1177/1074248413514481. Review.

PMID:
24363242
5.

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Chrysant SG, Ibrahim M.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. Review.

6.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

7.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Review.

PMID:
23932901
8.
9.

Fenofibrate in the treatment of dyslipidemia associated with HIV infection.

Samineni D, Fichtenbaum CJ.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):995-1004. doi: 10.1517/17425255.2010.504715. Review.

PMID:
20604734
10.

Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.

Sahebkar A, Watts GF.

Atherosclerosis. 2013 Sep;230(1):110-20. doi: 10.1016/j.atherosclerosis.2013.06.026. Review.

PMID:
23958262
11.

Treatment of dyslipidemia in HIV-infected patients.

Sekhar RV, Balasubramanyam A.

Expert Opin Pharmacother. 2010 Aug;11(11):1845-54. doi: 10.1517/14656566.2010.487484. Review.

PMID:
20486828
12.

Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals.

Botros D, Somarriba G, Neri D, Miller TL.

Curr HIV/AIDS Rep. 2012 Dec;9(4):351-63. doi: 10.1007/s11904-012-0135-7. Review.

13.

An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.

Bruno CB, Schapiro JM, Saberi P.

J Int Assoc Physicians AIDS Care (Chic). 2011 Jul-Aug;10(4):219-22. doi: 10.1177/1545109711404945. Review.

Items per page

Supplemental Content

Support Center